Allogene Therapeutics, Inc.
ALLO
$1.77
-$0.09-4.84%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.64M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.64M | -- | -- | -- | -- |
| Cost of Revenue | 30.72M | 32.00M | 28.63M | 31.16M | 40.16M |
| Gross Profit | -26.08M | -32.00M | -28.63M | -31.16M | -40.16M |
| SG&A Expenses | 20.84M | 14.09M | 13.77M | 13.74M | 14.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.56M | 46.09M | 42.40M | 44.90M | 54.44M |
| Operating Income | -46.92M | -46.09M | -42.40M | -44.90M | -54.44M |
| Income Before Tax | -42.68M | -42.61M | -38.81M | -41.40M | -50.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.68M | -42.61M | -38.81M | -41.40M | -50.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.68M | -42.61M | -38.81M | -41.40M | -50.94M |
| EBIT | -46.92M | -46.09M | -42.40M | -44.90M | -54.44M |
| EBITDA | -44.28M | -43.22M | -39.35M | -41.80M | -51.33M |
| EPS Basic | -0.13 | -0.18 | -0.17 | -0.19 | -0.23 |
| Normalized Basic EPS | -0.08 | -0.11 | -0.11 | -0.12 | -0.14 |
| EPS Diluted | -0.13 | -0.18 | -0.17 | -0.19 | -0.23 |
| Normalized Diluted EPS | -0.08 | -0.11 | -0.11 | -0.12 | -0.14 |
| Average Basic Shares Outstanding | 328.93M | 240.29M | 226.03M | 222.04M | 218.93M |
| Average Diluted Shares Outstanding | 328.93M | 240.29M | 226.03M | 222.04M | 218.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |